Type 1 Staging
Prospective longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct stages before the onset of symptoms. According to a new staging classification system, type 1 diabetes develops in three stages ( Table 2) . Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by two or more islet autoantibodies with normoglycemia and is presymptomatic. Stage 2 is the presence of b-cell autoimmunity with dysglycemia and is presymptomatic. Onset of symptomatic disease resulting from insulin deficiency in children with type 1 diabetes occurs at stage 3. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and may aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.
In patients with classic symptoms, measurement of blood glucose is sufficient to diagnose diabetes (symptoms of hyperglycemia or hyperglycemic crisis plus a random plasma glucose [PG] $200 mg/dL [11.1 mmol/L]). Classic symptoms, typically occurring for several days to a few weeks prior to diagnosis, may include polyuria, polydipsia, weight loss, polyphagia, fatigue, and blurred vision from lens swelling caused by the osmotic effects of chronic hyperglycemia (9) . Perineal candidiasis is a common symptom in young children and girls (10) . Approximately one-third of cases present with diabetic ketoacidosis (DKA) and, unfortunately, the numbers are increasing (11) . The characteristic biochemical featuresd hyperglycemia, glucosuria, ketonemia, and ketonuriadusually make the diagnosis of stage 3 diabetes obvious. Because a low renal glucose threshold may cause glycosuria without hyperglycemia or ketonuria, an elevated PG concentration must be documented in a laboratory to diagnose diabetes. The ADA's criteria for the diagnosis of stage 3 diabetes are shown in Table 3 . Blood glucose rather than A1C should be used to diagnose acute onset of type 1 diabetes in individuals with symptoms of hyperglycemia (9) . Clinical diagnostic criteria are the same for type 1 and type 2 diabetes.
Because the metabolic state of untreated children with type 1 diabetes can deteriorate rapidly, a definitive diagnosis should be made immediately. Delays in diagnosis and initiation of medical treatment, including insulin replacement therapy (see below), must be avoided. A glucose tolerance test is seldom required except in atypical cases or very early in the disease when PG values may be normal or only mildly abnormal and the diagnosis may be uncertain. Table 1 -ADA evidence-grading system for "Standards of Medical Care in Diabetes"
Level of evidence Description
A Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including c Evidence from a well-conducted multicenter trial c Evidence from a meta-analysis that incorporated quality ratings in the analysis Compelling nonexperimental evidence, i.e., "all or none" rule developed by the Centre for Evidence-Based Medicine at the University of Oxford Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including c Evidence from a well-conducted trial at one or more institutions c Evidence from a meta-analysis that incorporated quality ratings in the analysis B Supportive evidence from well-conducted cohort studies c Evidence from a well-conducted prospective cohort study or registry c Evidence from a well-conducted meta-analysis of cohort studies Supportive evidence from a well-conducted case-control study
C
Supportive evidence from poorly controlled or uncontrolled studies c Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results c Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls) c Evidence from case series or case reports Conflicting evidence with the weight of evidence supporting the recommendation
E
Expert consensus or clinical experience Screening for type 1 diabetes in asymptomatic children with a panel of autoantibodies is currently recommended only in the setting of research studies in first-degree family members of a proband with type 1 diabetes (9) . The incidental discovery of hyperglycemia without classic symptoms does not necessarily indicate new-onset diabetes, especially in young children with an acute illness who may experience "stress hyperglycemia." The risk of eventually developing diabetes, however, may be increased in some children with incidental or stress hyperglycemia, especially those with immunological, metabolic, or genetic markers for type 1 diabetes (12) (13) (14) , and consultation with a pediatric endocrinologist is indicated. In the asymptomatic child or adolescent screened because of a high risk for diabetes, a test with fasting plasma glucose (FPG) $126 mg/dL (7 mmol/L), 2-h PG $200 mg/dL (11.1 mmol/L), or A1C $6.5% should be repeated on a separate day to confirm the diagnosis. The ADA recommends that the same test be repeated without delay using a new blood sample (9) . The diagnosis is also confirmed if two different tests (such as A1C and FPG) are both above the diagnostic threshold; however, if the results are discordant, then the test whose result is above the diagnostic cut point should be repeated. The child or adolescent with typical symptoms of diabetes and a random PG $200 mg/dL (11.1 mmol/L) does not require a repeat value on another day or any further testing to diagnose diabetes. Glucose meters (and urine ketone tests) are useful for screening in clinics and physicians' offices, but the diagnosis of diabetes must be confirmed by measurement of venous PG on an analytic instrument in a clinical chemistry laboratory.
There is still debate over whether A1C and the same A1C cut point as in adults should be used to diagnose type 1 diabetes in children and adolescents (15) . The studies that formed the basis for recommending A1C for the diagnosis of diabetes included only adults, primarily those with type 2 diabetes. Also, A1C alone may be a poor diagnostic tool for prediabetes and type 2 diabetes in obese children and adolescents (16) . In a cohort of newly diagnosed children and adolescents with type 1 diabetes, all had an A1C value .6.6% (measured with a point-ofcare [POC] device), whereas A1C levels in children with transient hyperglycemia were between 4.5% and 6.1%. An A1C cutoff level of 6.35% had a 100% sensitivity and specificity for the diagnosis of type 1 diabetes (17) . Data from four separate prospective studies of high-risk subjects ,21 years of agedthe Diabetes Prevention Trial-Type 1 (DPT-1), The Environmental Determinants of Diabetes in the Young (TEDDY), Trial to Reduce IDDM in the Genetically at Risk (TRIGR), and Type 1 Diabetes TrialNet Natural History Study (A1C measured within 90 days of a diagnostic oral glucose tolerance test [OGTT] or fasting PG $126 mg/dL)d show that A1C $6.5% is a highly specific but not sensitive early indicator of type 1 diabetes diagnosed by OGTT or asymptomatic hyperglycemia (18) .
Although POC A1C assays may be certified by the NGSP (formerly the National Glycohemoglobin Standardization Program), proficiency testing is not mandated for performing the test; accordingly, POC assays for diagnostic purposes are not recommended. Further details on factors that may impact hemoglobin glycation and thus the A1C test, including age, race, and hemoglobinopathies, can be found in "Standards of Medical Care in Diabetes" (19) .
Distinguishing Diabetes Type
One often correctly assumes a diagnosis of type 1 diabetes in the slender prepubertal child with classic symptoms and without a family history suggestive of a monogenic form of diabetes. However, observational studies show increasing numbers of overweight and obese children and adolescents with type 1 diabetes (20), similar to the general population, and recent data from the T1D Exchange clinic registry indicate that in more than 11,000 U.S. children and adolescents with type 1 diabetes, 24% are overweight and an additional 15% are obese (21) . Moreover, in patients aged 10-17 years with a type 2 diabetes phenotype, 10% have evidence of islet autoimmunity (22) and some patients have pathophysiological features of both type 1 and type 2 diabetes (i.e., insulin deficiency and increased insulin resistance). Distinguishing between type 1 and type 2 diabetes in an overweight or obese adolescent, therefore, may be challenging, especially in ethnic/racial minorities. In such patients, a detailed family history and measurement of islet autoantibodies is recommended, and plasma or urinary C-peptide concentrations also may be helpful (22) (23) (24) .
Monogenic diabetes, which may account for ;1.2-4% of pediatric diabetes (25), is frequently misdiagnosed as type 1 diabetes and inappropriately treated with insulin (26). The minimum prevalence of monogenic diabetes in the U.S. pediatric population is approximately 2.1 per 100,000 (26). Clinicians should be alert to the possibility of maturity-onset diabetes of the young (MODY), particularly in antibody-negative youth with diabetes (26), and neonatal diabetes, particularly in children diagnosed with diabetes in the first 6 months of life. Making the diagnosis of MODY or neonatal diabetes has important implications for treatment of the patient and other affected family members (27) (see Table 4 ). The online probability calculator Table 3 -Criteria for the diagnosis of diabetes (9) FPG $126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.* OR 2-h PG $200 mg/dL (11.1 mmol/L) during an OGTT. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 1.75 g/kg up to a maximum of 75 g anhydrous glucose dissolved in water.* OR A1C $6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified † and standardized to the DCCT assay.* OR In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random PG $200 mg/dL (11.1 mmol/L).
Definitions are based on venous PG levels. WHO, World Health Organization. *In the absence of unequivocal hyperglycemia, the first three criteria should be confirmed by repeat testing. †See www.ngsp.org.
(www.diabetesgenes.org/content/modyprobability-calculator) can aid in the identification of individuals most likely to benefit from genetic testing, although the tool is still undergoing validation. Table 5 .
BLOOD GLUCOSE MANAGEMENT: MONITORING AND TREATMENT

Insulin
Continuous Subcutaneous Insulin Infusion
Once considered an alternative form of insulin delivery, continuous subcutaneous insulin infusion, or insulin pump therapy, is often used for children with type 1 diabetes (29). Meta-analyses of randomized controlled trials have shown modest differences between insulin pump therapy and injection regimens for improving glycemic control and reducing hypoglycemia (30-32). Results in children have thus far been equivocal (30,32,33). Large registries that track outcomes of type 1 diabetes treatment and long-term single-center observational studies do suggest children treated with continuous subcutaneous insulin infusion have lower A1C levels, lower hypoglycemia rates, improved diabetesrelated quality of life, higher treatment satisfaction, and less fear of hypoglycemia (34). Insulin pump studies that incorporate continuous glucose monitoring (CGM) devices used continuously demonstrate significant improvement in both glycemic control and hypoglycemia reduction in pediatric patients with suboptimal blood glucose control at baseline (35).
Assessment of Glycemic Control
Recommendations c A1C should be measured in all children and adolescents with type 1 diabetes at 3-month intervals to assess their overall glycemic control. E c An A1C target of ,7.5% should be considered in children and adolescents with type 1 diabetes but should be individualized based on the needs and situation of the patient and family. E c With increasing use of CGM devices, outcomes other than A1C, such as time with glucose in target range and frequency of hypoglycemia, should be considered in the overall assessment of glycemic control. E . Similar studies in children under 10 years old demonstrated satisfaction with devices but no measurable impact on A1C or hypoglycemia reduction (47,48). In the pediatric cohort of the Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) trial, subjects aged 7-18 years using insulin pumps plus CGM had a 0.6% reduction in A1C levels as well as significant reductions in glycemic variability compared with the group using injection therapy and no CGM; hypoglycemia exposure was not significantly different between groups (35).
Although it is still under 10%, recent reports from a U.S. diabetes registry estimate that CGM use in pediatric patients consistently increased between 2010-2012 and 2012-2014 (29) and sharply rose in 2014-2016 (49). The largest increase was in very young children (ages 2-5 years), in whom CGM use was approaching 40% (49). There have been improvements in CGM accuracy and performance (50). CGM is associated with lower mean A1C in youth for insulin pump users as well as patients using multiple daily injection regimens (51). For most CGM systems, confirmatory SMBG is required to make treatment decisions. However, the U.S. Food and Drug Administration (FDA) recently approved a CGM device (for ages 2 and older) for making treatment decisions without SMBG.
Automated Insulin Delivery
Recommendation c Automated insulin delivery systems appear to improve glycemic control and reduce hypoglycemia in children and should be considered in pediatric patients with type 1 diabetes. B
The combination of continuous glucose sensors with insulin pumps has enabled the development of automated insulin delivery systems ("closed-loop" or "artificial pancreas" devices). A controller algorithm adjusts insulin delivery rates based on a continuous stream of glucose sensor data. Suspending basal insulin delivery for low sensor glucose levels has been shown to markedly reduce hypoglycemia without worsening glycemia (52). Sensor-augmented pumps that preemptively suspend insulin delivery when sensor glucose levels are predicted to be low show promise in minimizing hypoglycemia (53,54). The greatest potential for improved glycemic control is the dynamic regulation of insulin delivery for both high and low glucose levels. "Hybrid" closed-loop systems, which modulate basal insulin delivery based on sensor glucose levels, have increased time spent within target glucose ranges, reduced hyper-and hypoglycemia exposure, lowered A1C levels, and improved measures of quality of life in both adult and adolescent subjects (55-58). Translation of automated insulin delivery from research to clinical care will require patient and provider education to optimize outcomes (59). Users must still count carbohydrates and bolus manually before meals. Systems that reduce reliance on carbohydrate counting and systems that administer glucagon under automated control to mitigate the risk of hypoglycemia remain in development (60) . A recent systematic review and meta-analysis of randomized controlled trials suggests that artificial pancreas systems uniformly improve glucose control in outpatient settings despite heterogenous technical and clinical factors (61).
Adjunctive Therapies
Recommendation c There is insufficient evidence to support the routine use of adjunctive medical therapies in children with type 1 diabetes. E Adjunctive therapies to treat type 1 diabetes, primarily targeting insulin resistance (during puberty and with obesity), have been investigated to assess potential benefit. However, clinical trials have failed to demonstrate a glycemic benefit of adding metformin (the only approved insulin sensitizer for use in the pediatric age range) to insulin in overweight and obese adolescents with type 1 diabetes, although some studies have shown weight loss and/or reductions in insulin requirements and cardiovascular disease (CVD) risk factors with adjunctive metformin (62, 63) . Pramlintide, an analog of the pancreatic polypeptide amylin, has been shown to improve glycemic control when added to insulin in adults with type 1 diabetes, primarily through dampening glycemic excursions by suppressing glucagon secretion and delaying gastric emptying. Neither pramlintide nor other potentially useful adjuncts, such as glucagonlike peptide 1 receptor agonists (e.g., liraglutide, exenatide) or sodium-glucose cotransporter 2 inhibitors, have been thoroughly studied in the pediatric population with type 1 diabetes, and none have been approved for use in this population by the FDA at the time of this writing.
LIFESTYLE MANAGEMENT
Lifestyle management is important for pediatric patients with type 1 diabetes and enables health maintenance, CVD prevention, and glycemic control. Lifestyle management includes healthful approaches to nutrition and exercise. Training young patients and their families in medical nutrition therapy and approaches to mitigating both the hypoand hyperglycemic effects of exercise is part of diabetes self-management education and support, which should be provided by a registered dietitian, a diabetes educator, an exercise specialist/ physiologist, and a pediatric endocrinologist. Extensive training should occur at diagnosis, with annual updates by the registered dietitian. Quarterly visits with the diabetes educator and endocrinologist ensure ongoing training throughout childhood and adolescence. (65) . The best approach to healthful eating is within the context of the family, focusing on healthy eating for all members. There is no single ideal dietary distribution of calories among carbohydrates, fats, and proteins for people with diabetes; therefore, macronutrient distribution should be individualized while keeping total calorie and metabolic goals in mind. Carbohydrate intake from vegetables, fruits, legumes, whole grains, and dairy products, with an emphasis on foods higher in fiber and lower in glycemic load, is preferred over other sources, especially those containing added sugars. Saturated fats should be limited. Caloric intake should fuel normal growth and development and avoid overweight and underweight, especially given the current trends, with at least one-third of pediatric patients with type 1 diabetes overweight or obese (21, 66, 67) .
Nutrition Therapy
Nutrition education begins with carbohydrate counting, where consistency, rather than accuracy, results in optimal glycemic outcomes (68) . Over-or undercalculating by up to 10 g or 15% of the carbohydrate amount is unlikely to yield substantial hypoglycemia or hyperglycemia, respectively (69, 70) . Persons lacking numeracy skills may use past experience to match insulin doses to carbohydrate intake.
Recent studies have shown that meals with protein, fat, and more complex carbohydrates delay glucose level increases and respond well to square-wave or dualwave bolus doses or the splitting of bolus doses given by injection (71) (72) (73) (74) . Exercise positively affects physical fitness, strength building, weight management, social interaction, self-esteem building, and creation of healthful habits for adulthood, but it also has the potential to cause both hypoglycemia and hyperglycemia. The type, intensity, and duration of exercise trigger multiple hormones (insulin, glucagon, catecholamines, and glucocorticoids) that mediate fuel metabolism (75) (76) (77) . Pancreatic islet cells achieve euglycemia by balancing peripheral glucose uptake and hepatic glucose production. In type 1 diabetes, this intrinsic balance does not exist. Exogenous insulin administration inhibits hepatic glucose production and promotes exercise-induced glucose uptake, both triggering hypoglycemia. Hyperglycemia may occur during high-intensity exercise such as sprints or resistance training when there is inadequate delivery of exogenous insulin and/or an excess of counterregulatory hormones that increase hepatic glucose production and inhibit glucose uptake into skeletal muscle.
Physical Activity and Exercise
Though the potential for hyperglycemia can frustrate patients and families, fear of exercise-induced hypoglycemia dominates clinical concerns. Intense exercise increases hypoglycemia risk during, immediately following, and 6-12 h after physical activity, the "lag effect" (78) . This lag likely results from a combination of improved insulin sensitivity following exercise, blunted counterregulatory hormone release, and increased glucose uptake by the liver and skeletal muscles to replenish glycogen stores. Impaired counterregulatory hormone release in pediatric patients may include blunting during sleep, antecedent hypoglycemia, and autonomic failure (79) (80) (81) . Delayed hypoglycemia often occurs at night following afternoon physical activities. Therefore, exercise-induced hypoglycemia and fear of hypoglycemia may limit desire to participate in exercise.
The following paragraphs outline strategies to mitigate hypoglycemia risk and minimize hyperglycemia with exercise. For in-depth discussions, see recently published reviews and guidelines (76, 77, 82) .
Overall, it is recommended that youth with type 1 diabetes participate in 60 min or more of daily physical activity, including resistance and flexibility training (83). Although uncommon in the pediatric population, patients should be medically evaluated for comorbid conditions or diabetes complications that may restrict participation in an exercise program. As hyperglycemia can occur before, during, and after physical activity, it is important to ensure that the elevated glucose level is not related to insulin deficiency that would lead to worsening hyperglycemia with exercise and ketosis risk. Intense activity should be postponed with marked hyperglycemia (glucose $350 mg/dL [19.4 mmol/L]), moderate to large urine ketones, and/or b-hydroxybutyrate .1.5 mmol/L. Caution may be needed when b-hydroxybutyrate levels are $0.6 mmol/L (76, 77) .
The prevention and treatment of hypoglycemia associated with physical activity include decreasing the prandial insulin for the meal/snack before exercise and/or increasing food intake. Patients on insulin pumps can lower basal rates by ;10-50% or more or suspend for 1-2 h during exercise (84). Decreasing basal rates or long-acting insulin doses by ;20% after exercise may reduce delayed exercise-induced hypoglycemia (85) . Accessible rapid-acting carbohydrates and frequent blood glucose monitoring before, during, and after exercise, with or without CGM, maximize safety with exercise.
Blood glucose targets prior to exercise should be 90-250 mg/dL (5.0-13.9 mmol/L). Consider additional carbohydrate intake during and/or after exercise, depending on the duration and intensity of physical activity, to prevent hypoglycemia. For low-to moderate-intensity aerobic activities (30260 min), and if the patient is fasting, 10215 g of carbohydrate may prevent hypoglycemia (86) . After insulin boluses (relative hyperinsulinemia), consider 0.5-1.0 g of carbohydrates/kg per hour of exercise (;30260 g), which is similar to carbohydrate requirements to optimize performance in athletes without type 1 diabetes (87-89). Age-Groups Table 6 illustrates typical development and diabetes demands and priorities across childhood, updated from the original version (1). The responsibility for and supervision of type 1 diabetes management falls largely to the primary caregiver during the early years of childhood, with a gradual transition to other caregivers and school personnel as the child ages. However, the primary caregiver will remain a major part of type 1 diabetes management through adolescence.
BEHAVIORAL ASPECTS OF SELF-MANAGEMENT
Unique Challenges of Adolescence
The adolescent years may disrupt diabetes care and communication between family members, youth, and providers. Hallmarks of normal adolescence are increased independence in decision making and reliance on the peer group for validation of self-concept and self-worth. Wishing to "fit in" may contribute to youth hiding or minimizing diabetes care behaviors, thereby compromising management in the school setting (91). Cognitive development and medical decision-making skills will impact a wide variety of risktaking behaviors and acceptance of selfmanagement behaviors into daily life (92,93). Suboptimal glycemic management should not automatically be attributed to adolescent rebellion or lack of concern for health. A thorough, ageappropriate psychosocial evaluation and review of the medical regimen will suggest targets for modification to facilitate selfmanagement and well-being. If the adolescent is resistant to accepting support from clinicians, family, and friends, the possibility of a more serious psychological issue must be considered and evaluated.
For these reasons, adolescents should be offered time by themselves with their care provider(s) starting at age 12 years. Care should be taken to respect the privacy of teens/young adults, especially regarding behaviors that are considered taboo or risky (94). Discussions with adolescents should include questions about well-being in general, diabetes distress, and risk behaviors (e.g., substance use and sexual activity) (95, 96) . It is recommended that prior to or shortly after puberty, girls with type 1 diabetes should be counseled about the importance of good metabolic control prior to conception and should be made aware that safe and effective family planning methods are available should they become sexually active and not desire pregnancy.
Screening, Prevention, and Treatment
Given the rapid and dynamic nature of cognitive, developmental, and emotional changes in youth, early detection of depression, anxiety disorders, disordered eating (97) , and learning disabilities enhances the range and effectiveness of potential treatment options and may help to minimize adverse effects on diabetes management and disease outcomes. Although rates of psychological distress and disorders in children with type 1 diabetes may not differ from the general population, adolescents with type 1 diabetes do tend to show 2-3 times the rate of psychological distress as their peers without diabetes (98) (99) (100) (101) . Distinguishing between frank depressive or anxiety disorders and diabetesrelated distress should be left to mental health providers so that appropriate treatment options can be determined.
Because youth depend on social support systems (family and care providers) and must eventually transition to independent diabetes self-management as adults, their families and related social networks should be included in psychosocial assessment and treatment (102) (103) (104) . Teaching family members effective problem-solving and conflict-resolution skills can improve diabetes management and facilitate better glycemic control, with the potential to reduce diabetes distress and improve quality of life (102, 105, 106) . Parents of children with type 1 diabetes are prone to high rates of depression, especially around the time of diagnosis (107,108) . Persistence of parental depression is associated with poorer child adjustment and diabetes management, especially in younger children (109) .
Emerging technologies, like phone and computer transmission of glucose and insulin management data, can be useful in maintaining communication of information through nonconfrontational channels and may provide a means for youth (114) . Oral carbohydrate (15 g ) is the preferred treatment for patients with blood glucose ,70 mg/dL (3.9 mmol/L) or those with symptoms of hypoglycemia who are alert and able to eat. Glucagon is used for severe hypoglycemia. In children, small studies have led to age-based minidoses of glucagon (0.02-0.15 mg) if the child is alert but not able to eat (115) . Alternate delivery methods for glucagon are in development (116) .
Microvascular Complications
Retinopathy, diabetic kidney disease (DKD) (previously referred to as "nephropathy"), and neuropathy are rarely reported in prepubertal children and children with diabetes duration of only 1-2 years; however, complications may occur after the onset of puberty or after 5-10 years of diabetes (117) . It is recommended that clinicians with expertise in diabetes management should counsel the pediatric patient and family on the importance of early prevention and intervention.
DKD Recommendations
c Annual screening for albuminuria with a random (morning sample preferred to avoid effects of exercise) spot urine sample for albumin-to-creatinine ratio should be considered at puberty or at age .10 years, whichever is earlier, once the child has had diabetes for 5 years. B c An ACE inhibitor or an angiotensin receptor blocker (ARB), titrated to normalization of albumin excretion, may be considered when elevated urinary albumin-to-creatinine ratio (.30 mg/g) is documented (two of three urine samples obtained over a 6-month interval following efforts to improve glycemic control and normalize blood pressure). E Screening provides an opportunity to detect albuminuria early, initiate ACE inhibitor or ARB therapy, particularly in the presence of hypertension, and encourage meticulous attention to achieving glycemic goals, especially during the reversible phase of DKD (118). Evaluation for possible nondiabetic kidney disease should be considered as part of the clinical evaluation. If females are prescribed ACE inhibitors/ARBs, they should be counseled on the teratogenic risks associated with pregnancy (refer to "Standards of Medical Care in Diabetes" for additional guidance on pharmacologic treatment of hypertension [119] ). Hypertension, or even a rise in blood pressure within the normal range, may accompany progression to albuminuria (120) or its persistence (121) . Risk factors for DKD include poor glycemic control, smoking, a parent with essential hypertension, and a family history of DKD or CVD (122) . Even in the absence of hypertension, an ACE inhibitor or ARB may reverse increased albumin excretion or delay the progression to albuminuria (123) (124) (125) . In adults with diabetes, treatment of elevated albumin excretion in the absence of hypertension is not recommended (126) . Data on the long-term benefit of these therapies are needed to support the benefit on long-term vascular disease risk reduction (127, 128 
Macrovascular Complications
CVD, cerebrovascular disease, and peripheral vascular disease resulting from atherosclerosis are leading causes of morbidity and mortality in adults with type 1 diabetes (140-142). Factors contributing to atherosclerosis and elevated plasma lipid concentrations in children and youth include smoking, hypertension, obesity, family history of heart disease, and diabetes (143, 144) . Diabetes is an independent risk factor for CVD in adults, conferring a two-to fourfold increased incidence of CVD. There is unequivocal evidence that the atherosclerotic process begins in childhood (145) (146) (147) , and although CVD events are not expected to occur during childhood, various methodologies show that youth with type 1 diabetes may have subclinical CVD abnormalities within the first decade of diagnosis (148) (149) (150) . Population-based studies estimate that 14-45% of children with type 1 diabetes have two or more CVD risk factors (151) (152) (153) . The American Heart Association published a joint statement with the ADA on CVD in type 1 diabetes (143) and a scientific statement on CVD risk factors in youth with diabetes (144).
Hypertension
Recommendations c Blood pressure should be measured at each routine visit. Children found to have high-normal blood pressure (systolic blood pressure or diastolic blood pressure at the 90th percentile for age, sex, and height) or hypertension (systolic blood pressure or diastolic blood pressure at the 95th percentile for age, sex, and height) should have blood pressure confirmed on three separate days. B c Initial treatment of high-normal blood pressure (systolic blood pressure or diastolic blood pressure consistently at the 90th percentile for age, sex, and height) includes dietary modification and increased exercise, if appropriate, aimed at weight control. If target blood pressure is not reached with 3-6 months of initiating lifestyle intervention, pharmacologic treatment should be considered. E c In addition to lifestyle modification, pharmacologic treatment of hypertension (systolic blood pressure or diastolic blood pressure consistently at the 95th percentile for age, sex, and height) should be considered as soon as hypertension is confirmed. E c ACE inhibitors or ARBs should be considered for the initial pharmacologic treatment of hypertension, following reproductive counseling because of the potential teratogenic effects of both drug classes. E c Treatment goal is blood pressure consistently ,90th percentile for age, sex, and height. E Blood pressure measurements should be determined using the appropriate size cuff with the child seated and relaxed. Parental hypertension is a major risk factor for elevated blood pressure in childhood and should be evaluated. Normal blood pressure levels for age, sex, and height and appropriate methods for measurement are available online at www.nhlbi.nih.gov/health/prof/heart/ hbp/hbp_ped.pdf. Treatment for hypertension is generally an ACE inhibitor, but an ARB may be used if the ACE inhibitor is not tolerated. Hypertension diagnosis in children with diabetes is often delayed and undertreated (154) . If hypertension is documented, pathological causes other than DKD should be excluded. Laboratory examination should include evaluation of renal functional status (urinalysis, serum creatinine, and blood urea nitrogen) and urinary albumin excretion (if not obtained within the previous 6 months).
Dyslipidemia
Recommendations c Obtain a fasting lipid profile in children 10 years of age or older as soon as convenient after the diagnosis of diabetes (once glycemic control has been established). E c If LDL cholesterol values are within the accepted risk level (,100 mg/ dL [2.6 mmol/L]), a lipid profile repeated every 3-5 years is reasonable. E c If lipids are abnormal, initial therapy should consist of optimizing glucose control and medical nutrition therapy using a Step 2 American Heart Association diet that restricts saturated fat to 7% of total calories and dietary cholesterol to 200 mg/day, which is safe and does not interfere with normal growth and development. B c After 10 years of age, consider adding a statin in patients who, despite medical nutrition therapy and lifestyle changes for 6 months, continue to have LDL cholesterol .160 mg/dL (4.1 mmol/L) or LDL cholesterol .130 mg/dL (3.4 mmol/L) and one or more CVD risk factors, following reproductive counseling because of the potential teratogenic effects of statins. E c Therapy goal is an LDL cholesterol value ,100 mg/dL (2.6 mmol/L). E For children with a significant family history of CVD, the National Heart, Lung, and Blood Institute recommends obtaining a fasting lipid panel beginning at 2 years of age (155) . Abnormal results from a random lipid panel should be confirmed with a fasting lipid panel. SEARCH study data show that improved glucose control over a 2-year period is associated with a more favorable lipid profile; however, improved glycemic control alone is unlikely to normalize lipids in youth with type 1 diabetes and dyslipidemia (156, 157) . Initial treatment should include medical nutrition therapy and a diet restricting saturated fats (158) . Neither long-term safety nor cardiovascular outcome efficacy of statin therapy has been established for adolescents; however, studies have shown short-term safety equivalent to that seen in adults and efficacy in lowering LDL cholesterol levels in familial hypercholesterolemia or severe hyperlipidemia, improving endothelial function, and causing regression of carotid intimal thickening (129, 159, 160) . The AdDIT study demonstrated the safety of statin use over 2-4 years in adolescents with type 1 diabetes. This study showed significant reductions in total, LDL, and non-HDL cholesterol levels, in triglyceride levels, and in ratios of apolipoprotein B to apolipoprotein A1. However, statin use had no significant effects on carotid intima-media thickness, other cardiovascular markers, the GFR, or retinopathy progression (129) . Statins are not approved for patients aged ,10 years, and statin treatment should generally not be used in children with type 1 diabetes before this age. Statins are contraindicated in pregnancy; therefore, pregnancy prevention is of paramount importance for postpubertal girls.
Smoking Recommendation c Elicit a smoking history at initial and follow-up diabetes visits, and discourage smoking in youth who do not smoke and encourage smoking cessation in those who do smoke. A
The adverse health effects of smoking are well recognized with respect to future cancer and risk of vascular disease (161) . Cigarette smoking cessation, including e-cigarettes, is an important part of routine diabetes care, as is assessment of exposure to secondhand smoke. (175) . The challenging dietary restrictions associated with having both type 1 diabetes and celiac disease are a significant burden. Therefore, a biopsy to confirm the diagnosis of celiac disease is recommended, especially in asymptomatic children, before prescribing significant dietary changes (176) . Some patients and providers may choose to start a gluten-free diet without a biopsy in the presence of a high antibody titer and symptoms of celiac disease. Genetic screening (HLA-DQ2 and HLA-DQ8) confirms high risk for celiac disease (177) .
Autoimmune Conditions
TRANSITION FROM PEDIATRIC TO ADULT CARE
Recommendations c Pediatric diabetes providers should begin to prepare youth for transition in early adolescence and, at the latest, at least 1 year before the transition to adult health care. E c Both pediatric and adult diabetes care providers should provide support and resources for transitioning young adults. E
The developmental stage of emerging adulthood is characterized by competing educational, social, vocational, and financial priorities (178) . During this phase, youth experience decreasing parental support and become fully responsible for their diabetes care, which may trigger a decline in medication-taking behavior and difficulty achieving blood glucose targets (179) . Consequently, young adults with type 1 diabetes are at risk for acute diabetes complications, chronic macrovascular and microvascular complications, psychosocial challenges, and early mortality (180) (181) (182) . An ineffective transition from pediatric to adult diabetes care may contribute to fragmentation of health care and increased risk for adverse outcomes. Prior research has highlighted challenges in the transition process, including gaps between pediatric and adult care (183, 184) , suboptimal transition preparation (184), deterioration of glycemic control (185, 186) , and increased hospitalizations (187) .
Available data suggest that many young adults in the U.S. do not transition to adult care until their early to mid-twenties (186, 188) , but timing is highly variable. There is no clear optimal transition age, and the overriding priority is to ensure consistent follow-up. An individualized approach to transition timing is recommended, prioritizing the developmental needs and preferences of the patient.
The ADA and numerous professional societies recommend that pediatric diabetes providers begin transition preparation during the early adolescent years but, at the latest, at least 1 year prior to transfer (94). Preparation should include patient counseling on diabetes selfmanagement, the differences between pediatric and adult care systems, the coordination of transfer, direct communication with receiving adult providers, and a written care summary.
Please refer to ADA's Position Statement (94) for a comprehensive discussion regarding the challenges of emerging adulthood and specific transition care recommendations. Organizations including Got Transition (189) and the Endocrine Society (190) have developed transition tools for clinicians, patients, and families. Clinical trials to study interventional approaches to transition preparation and transfer coordination, in order to optimize biomedical and psychosocial outcomes, are still needed.
CONCLUSIONS
Multicenter collaborative research and technological advances have increased type 1 diabetes disease understanding and led to advances in treatment. However, management of type 1 diabetes in youth remains imperfect, requiring unending vigilance and behavioral intervention. While it is burdensome to all affected individuals and their families, it is particularly challenging to those with limited resources and skills. Interdiction studies have yet to accomplish their goals of preventing and preserving b-cell function.
Type 1 diabetes requires youth to conform their lifestyle and behavior to a diabetes care regimen to control disease outcomes. In young children (under 6 years old), sick-day management, hypoglycemia unawareness, and caregiver issues are common but are manageable with education and attentiveness (191) . When adolescents seek independence, caregivers must carefully balance autonomy with supervision. Caregivers should not delegate all diabetes care to the youth, as adolescents often need more, not less, support during this challenging developmental period. There is a dearth of quality research on high-risk behaviors (e.g., illicit drug use, alcohol and tobacco use, unprotected sexual activity, and disordered eating) in youth with type 1 diabetes, although the few studies suggest that rates are similar to the general population (96) . However, in youth with type 1 diabetes, the combination of high-risk behaviors and dysglycemia are potentially disastrous. Health care providers should meet with youth alone and conduct a comprehensive HEADSS (home, education, eating, activities, drugs, sexuality, suicide/depression, and safety) assessment, incorporating diabetes as appropriate.
Engaging youth in highly supervised and supportive environments, such as diabetes camps, provides real-time education and reinforces the concept that they are not alone. A recent study in emerging adults with type 1 diabetes showed that young adults with diabetes fared comparably to their peers without diabetes in life path decisions, health behaviors, and psychological well-being (192) . Psychosocial research studies that evaluate quality-of-life measures and effective behavioral interventions in youth with type 1 diabetes are critically important.
Technological advances have revolutionized diabetes management with novel hardware, software, and the ability to capture endless streams of data. Improved data quality, including improving current methods to translate data from diabetes devices to patient, family, and provider use, are needed to transform clinical care. Future clinical studies should evaluate how best to leverage the technology tools and efficiently analyze and translate the data generated into diabetes management. Patients would benefit from device manufacturers enabling data interoperability, regulatory agencies expediting and harmonizing approvals, and payors reimbursing the numerous supplies needed to optimize type 1 diabetes management in a timely manner, especially for the pediatric population. All patients with type 1 diabetes should have access to appropriate insulin therapy and advanced diabetes technologies.
Parallel to the technological advances, ongoing research is required to better understand the complexities involving epidemiology, pathophysiology, complications, and quality of life and to improve long-term outcomes associated with the disease in pediatrics. Adult diabetes research trials often do not include youth, and it is unclear how many, if any, of the findings apply to the pediatric population; therefore, inclusion of a diverse pediatric population is needed. Preserving b-cell function and ultimately preventing type 1 diabetes is the aim. 
